About
Peter Damsbo, MD, joined Ventac Partners as Partner in June 2009. He has more than 25 years of experience from life science industry and science, including several years in the United States heading up clinical development of diabetes products for Novo Nordisk. Key positions prior to joining Ventac Partners include Chief Medical Officer at Zealand Pharma, Vice President Clinical Drug Development at Novo Nordisk Headquarter, Medical Director Diabetes at Novo Nordisk USA, and Research Fellow at the Steno Diabetes Center. During his industry career, Peter Damsbo has carried 3 medical projects from preclinical phase through to worldwide registration, and conducted numerous drug concept evaluations as well as been involved in drug licensing deals and due diligence processes. Peter Damsbo has an extensive experience in interacting with the health authorities in a number of countries, including most notably FDA and EMEA. Peter Damsbo medical expertise spans over several therapeutic areas,
Position in the VCSift Database
- • 14 investors at Ventac Partners are tracked.
- • 2,531 investors hold the Partner role in VCSift. Peter Damsbo is one of them.
- • 666 investors are based in Copenhagen, Hovedstaden, Denmark.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Copenhagen, Denmark
Contact Information
Find more investors like Peter
Search Investors